Compare Check Point Software Technologies Ltd (CHKP) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Check Point Software Technologies Ltd vs Summit Therapeutics Inc — how do they compare? Check Point Software Technologies Ltd trades at $132.07 (market cap $13.97B), while Summit Therapeutics Inc trades at $15.07 (market cap $12.01B). The key difference: Check Point Software Technologies Ltd is the larger of the two by market cap. Which is the better fit depends on your goals.
| CHKP | SMMT | |
|---|---|---|
Market Cap | $13.97B | $12.01B |
Sector | Technology | Health |
52-Week High | $223.00 | $29.32 |
52-Week Low | $112.47 | $13.05 |
Enterprise Value | $13.17B | $11.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CHKP trades at $134.32, up 1.99% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 38.37% net income margin and trades at a P/E of 13.82. Recent news highlights AI security partnerships and upcoming Q2 2026 earnings on July 30, 2026.
Outlook is mixed: analyst consensus targets $148.43 (10.5% upside) with 46% buy ratings, but technicals and insider sales pose risks. Key catalysts include AI integration progress and earnings results, while competition and sector volatility remain headwinds.
Summit Therapeutics (SMMT) trades at $15.30, showing modest daily gains of 0.33%. The stock faces bearish technical signals with negative cash flows and substantial losses (-$1.08B net income in 2025). Recent developments include the sale of Phase III asset ridinilazole and positive clinical trial results for ivonescimab. Analyst sentiment remains optimistic with 67% buy ratings and a $15.57 consensus target, though financial metrics show concerning profitability with -270.95% ROE.
SMMT presents a high-risk, catalyst-driven opportunity with binary outcomes dependent on clinical success. The company's heavy reliance on ivonescimab development creates significant upside potential but also substantial execution risk. Negative cash flow trends and persistent losses require careful monitoring of upcoming Q2 2026 earnings and clinical milestones for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
